Id |
Subject |
Object |
Predicate |
Lexical cue |
T11 |
0-207 |
Sentence |
denotes |
COVID-19 infection presents a risk of severe clinical outcome due to a dysregulated inflammatory syndrome [1,2] generated by Mononuclear Phagocytes [3], a major source of pro-inflammatory secretion products. |
T12 |
208-433 |
Sentence |
denotes |
Evidence from influenza [4,5] and previous SARS and MERS [6] patients, indicates that blood monocytes respond to tissue encounters in a two-stage mechanism of activation [7], which is not specific to the initiating infection. |
T13 |
434-560 |
Sentence |
denotes |
This is particularly relevant in COVID-19 where age and predisposing comorbidities enhance the risk of a severe outcome [8,9]. |
T14 |
561-742 |
Sentence |
denotes |
Tests are available to detect infectious virus and anti-viral antibody, but RNA alone is not proof of active infection and antibodies may not neutralize, but enhance infection [10]. |
T15 |
743-911 |
Sentence |
denotes |
In order to stratify patients at risk of a hyperinflammatory storm and prolonged recovery, we developed a novel blood test to assess their level of monocyte activation. |
T16 |
912-1022 |
Sentence |
denotes |
It uses the canonical CSF1R–CSF1 growth factor receptor [11], to characterize all monocytes in blood, Fig. 1 . |
T17 |
1023-1274 |
Sentence |
denotes |
Further steps include measures of priming during haematopoiesis along myeloid differentiation pathways mediated by CSF2R [12] and CSF3R, and testing their full activation potential by selected stimuli, in vitro, as surrogates of activation in tissues. |
T18 |
1275-1465 |
Sentence |
denotes |
Tests can also be used to evaluate macrophage contributions to efficacy of vaccines, anti-viral and anti- inflammatory agent trials, to diminish the risk of treatments and facilitate repair. |
T19 |
1466-1534 |
Sentence |
denotes |
Fig. 1 Monocytes represent a window between bone marrow and tissues. |
T20 |
1535-1796 |
Sentence |
denotes |
Blood monocytes are circulating intermediates between haematopoiesis in bone marrow and recruitment to tissues in response to turnover of resident macrophages of embryonic origin, and to increased demands following tissue inflammation, infection and malignancy. |
T21 |
1797-1947 |
Sentence |
denotes |
The CSF1 Receptor is a pan-monocyte marker expressed by all subsets of monocytes defined by CD14, CD16 and DCs, lacking both of these antigen markers. |
T22 |
1948-2145 |
Sentence |
denotes |
Together with CSF2R and CSF3R, these three lineage differentiation markers enable identification of distinct streams of monocytic, granulocytic and Dendritic cell types of monocyte differentiation. |
T23 |
2146-2342 |
Sentence |
denotes |
In response to the prototypic TH1 or TH2 cytokines, IFNγ and Interleukin 4/13, monocytes are polarized to distinct M1-like, classically activated, and M2-like, alternatively activated macrophages. |
T24 |
2343-2458 |
Sentence |
denotes |
Each becomes fully activated by further local phagocytic stimulation by microbes and apoptotic cells, respectively. |
T25 |
2459-2612 |
Sentence |
denotes |
CD40 and CD64 are M1-like markers, where CD40 is for detecting TLR4 pathway and CD64 is for detecting IFNγ activation, while CD200R is an M2-like marker. |
T26 |
2613-2657 |
Sentence |
denotes |
Other markers can be introduced as required. |